Anti-angiogenic agents in ovarian cancer: Dawn of a new era?

Current Oncology Reports

Volumn 13, Issue 6, 2011, Pages 450-458

  Liu, Joyce ^a   Matulonis, Ursula A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Anti angiogenic therapy; Bevacizumab; Cediranib; Ovarian cancer; Tyrosine kinase inhibitor (TKI); VEGF

Indexed keywords

AFLIBERCEPT; AMG 386; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; GEMCITABINE; INTEDANIB; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CONVULSION; CYTOREDUCTIVE SURGERY; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG COST; DRUG DOSE SEQUENCE; DRUG FATALITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; INTERMETHOD COMPARISON; INTESTINE PERFORATION; KIDNEY FAILURE; MOLECULAR PATHOLOGY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; PROTEINURIA; RECURRENT CANCER; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS;

EID: 81155151896     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-011-0194-8     Document Type: Article

References (53)

1. A Jemal R Siegel J Xu E Ward 2010 Cancer statistics, 2010 CA Cancer J Clin 60 5 277 300 20610543 10.3322/caac.20073
2. A Jemal F Bray MM Center J Ferlay E Ward D Forman 2011 Global cancer statistics CA Cancer J Clin 61 2 69 90 21296855 10.3322/caac.20107
3. SA Cannistra 2004 Cancer of the ovary N Engl J Med 351 24 2519 29 15590954 10.1056/NEJMra041842 1:CAS:528:DC%2BD2cXhtVGksbbM (Pubitemid 39603165)
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Available at http://www.nccn.org/professionals/physician-gls/f- guidelines.asp. Accessed June 2011.
5. S Ramakrishnan IV Subramanian Y Yokoyama M Geller 2005 Angiogenesis in normal and neoplastic ovaries Angiogenesis 8 2 169 82 16211363 10.1007/s10456-005-9001-1 1:STN:280:DC%2BD2Mnis1Oqug%3D%3D (Pubitemid 41712846)
6. L Martin R Schilder 2007 Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition J Clin Oncol 25 20 2894 901 17617520 10.1200/JCO.2007.11.1088 1:CAS:528:DC%2BD2sXosFSgtbw%3D (Pubitemid 47123153)
7. HC Hollingsworth EC Kohn SM Steinberg ML Rothenberg MJ Merino 1995 Tumor angiogenesis in advanced stage ovarian carcinoma Am J Pathol 147 1 33 41 7541612 1:STN:280:DyaK2MzivVKhsw%3D%3D
8. O Abulafia WE Triest DM Sherer 1997 Angiogenesis in primary and metastatic epithelial ovarian carcinoma Am J Obstet Gynecol 177 3 541 7 9322621 10.1016/S0002-9378(97)70143-1 1:STN:280:DyaK2svmtl2hsg%3D%3D (Pubitemid 27413766)
9. AA Alvarez HR Krigman RS Whitaker RK Dodge GC Rodriguez 1999 The prognostic significance of angiogenesis in epithelial ovarian carcinoma Clin Cancer Res 5 3 587 91 10100710 1:STN:280:DyaK1M7pvVyjuw%3D%3D (Pubitemid 29131968)
10. WM Merritt AK Sood 2007 Markers of angiogenesis in ovarian cancer Dis Markers 23 5-6 419 31 18057525 1:CAS:528:DC%2BD2sXhtlGjtL7P (Pubitemid 350171264)
11. L Zhang N Yang JR Garcia, et al. 2002 Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma Am J Pathol 161 6 2295 309 12466143 10.1016/S0002-9440(10)64505-1 1:CAS:528:DC%2BD38Xpslelsr4%3D (Pubitemid 35434873)
12. BC Cooper JM Ritchie CL Broghammer, et al. 2002 Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer Clin Cancer Res 8 10 3193 7 12374688 1:CAS:528:DC%2BD38XosFKhsb4%3D (Pubitemid 35155030)
13. SK Kassim EM El-Salahy ST Fayed, et al. 2004 Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients Clin Biochem 37 5 363 9 15087251 10.1016/j.clinbiochem. 2004.01.014 1:CAS:528:DC%2BD2cXjt1Cns7c%3D (Pubitemid 38490454)
14. L Li L Wang W Zhang, et al. 2004 Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer Anticancer Res 24 3b 1973 9 15274387 1:CAS:528: DC%2BD2cXmsV2jurk%3D (Pubitemid 38954620)
15. LA Hefler R Zeillinger C Grimm, et al. 2006 Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer Gynecol Oncol 103 2 512 7 16750560 10.1016/j.ygyno.2006.03.058 1:CAS:528: DC%2BD28XhtFegur7J (Pubitemid 44740099)
16. • Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25(33):5165-71. This is one of the two initial papers demonstrating single-agent activity of bevacizumab in recurrent ovarian cancer. (Pubitemid 350237599)
17. • Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25(33):5180-6. This is one of the two initial papers demonstrating single-agent activity of bevacizumab in recurrent ovarian cancer, and also the first report of a higher than expected risk of GI perforation in selected patients with ovarian cancer. (Pubitemid 350232248)
18. UA Matulonis S Berlin P Ivy, et al. 2009 Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer J Clin Oncol 27 33 5601 6 19826113 10.1200/JCO.2009.23.2777 1:CAS:528:DC%2BC3cXhtVWit7g%3D
19. Hirte H, Vidal L, Fleming G, et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial. J Clin Oncol 2008;26(May 20 suppl):Abstract 5521.
20. Tew WP, Colombo N, Ray-Coquard I, et al. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study. J Clin Oncol 2007;25(June 20 suppl):Abstract 5508.
21. JJ Biagi AM Oza HI Chalchal, et al. 2011 A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study Ann Oncol 22 2 335 40 20705911 10.1093/annonc/mdq357 1:STN:280:DC%2BC3M7ltFWltQ%3D%3D
22. Campos S, Penson RT, Berlin S, Matulonis UA, Horowitz N. A phase II trial of sunitinib in recurrent and refractory ovarian, fallopian tube, and peritoneal carcinoma. Gynecol Oncol 2010;116(3 (Suppl 1)):S119-S120; Abstract 306.
23. Friedlander M, Hancock KC, Benigno B, et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: results of a Phase II study. Ann Oncol 2008;19(Suppl 8):viii211; Abstract 6630.
24. Matei D, Sill MW, DeGeest K, Bristow RE. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol 2008;26(May 20 suppl):Abstract 5537.
25. AA Garcia H Hirte G Fleming, et al. 2008 Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia J Clin Oncol 26 1 76 82 18165643 10.1200/JCO.2007.12.1939 1:CAS:528:DC%2BD1cXhsVCrsLc%3D
26. Rose PG, Drake R, Braly PS, et al. Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. J Clin Oncol 2009;27(May 20 suppl):Abstract 5546.
27. Tillmanns TD, Lowe MP, Schwartzberg LS, Walker MS, Stepansk EJ. A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. J Clin Oncol 2010;28(May 20 suppl):Abstract 5009.
28. JP Micha BH Goldstein MA Rettenmaier, et al. 2007 A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer Int J Gynecol Cancer 17 4 771 6 17343605 10.1111/j.1525-1438.2007.00886.x 1:STN:280:DC%2BD2svhsFGktQ%3D%3D (Pubitemid 47063333)
29. RT Penson DS Dizon SA Cannistra, et al. 2010 Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors J Clin Oncol 28 1 154 9 19917843 10.1200/JCO.2009.22.7900 1:CAS:528:DC%2BC3cXhtF2rsrk%3D
30. DG Teoh AA Secord 2011 Antiangiogenic therapies in epithelial ovarian cancer Cancer Control 18 1 31 43 21273978
31. UA Matulonis 2011 Bevacizumab and its use in epithelial ovarian cancer Future Oncol 7 3 365 79 21323425 10.2217/fon.10.167 1:CAS:528: DC%2BC3MXjsFCktbg%3D
32. RA Burger 2011 Overview of anti-angiogenic agents in development for ovarian cancer Gynecol Oncol 121 1 230 8 21215996 10.1016/j.ygyno.2010.11.035 1:CAS:528:DC%2BC3MXjs1Wrs7o%3D
33. Dizon DS. Where do Antiangiogenic Agents Belong in the Treatment Algorithm for Ovarian Cancer? Am J Clin Oncol 2011. Epub ahead of print. Available at http://journals.lww.com/amjclinicaloncology/pages/default.aspx. Accessed June 2011.
34. DK Armstrong B Bundy L Wenzel, et al. 2006 Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 1 34 43 16394300 10.1056/NEJMoa052985 1:CAS:528:DC%2BD28XhvV2qsQ%3D%3D (Pubitemid 43048949)
35. N Katsumata M Yasuda F Takahashi, et al. 2009 Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial Lancet 374 9698 1331 8 19767092 10.1016/S0140-6736(09)61157-0 1:CAS:528:DC%2BD1MXht1Ogu7fJ
36. •• Burger RA, Brady MF, Bookman MA, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol 2010;2010(June 20 suppl):Abstract LBA1. This is the first report of the clinical activity of bevacizumab in the adjuvant setting in a phase 3 trial, demonstrating a progression-free survival benefit when combined with carboplatin and paclitaxel chemotherapy and continued as a maintenance therapy for 1 year. Overall survival data are not yet mature.
37. •• Perren T, Swart AM, Pfisterer J, et al. ICON7: A Phase III randomised Gynaecologic Cancer Intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or fallopian tube cancer (FTC). Ann Oncol 2010;21(Suppl 8):viii2-viii3; Abstract LBA4. This is the second phase 3 trial exploring the clinical activity of bevacizumab in the adjuvant setting, again demonstrating progression-free survival benefit when combined with carboplatin and paclitaxel chemotherapy and continued as maintenance therapy. Overall survival data are not yet mature.
38. • Kristensen GB, Perren T, Qian W, et al. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J Clin Oncol 2011;29(June 20 suppl):Abstract LBA5006. This is an update of the ICON7 trial.
39. ML Hensley 2011 Big costs for little gain in ovarian cancer J Clin Oncol 29 10 1230 2 21383287 10.1200/JCO.2010.34.0489
40. • Cohn DE, Kim KH, Resnick KE, et al. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011;29(10):1247-51. This is a cost-effectiveness exploration of the financial costs associated with bevacizumab therapy in the first-line adjuvant setting.
41. RS Braithwaite DO Meltzer JT King Jr, et al. 2008 What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 46 4 349 56 18362813 10.1097/MLR.0b013e31815c31a7
42. NCT01015118. BIBF 1120 or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer. Available at http://www.clinicaltrials.gov/ct2/show/NCT01015118. Accessed June 2011.
43. NCT00951496. Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. Available at http://www.clinicaltrials.gov/ct2/show/NCT00951496. Accessed June 2011.
44. NCT01167712. Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer. Available at http://www. clinicaltrials.gov/ct2/show/NCT01167712. Accessed June 2011.
45. •• Aghajanian C, Finkler NJ, Rutherford T, et al. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol 2011;29(June 20 suppl):Abstract LBA5007. This is the first report of phase 3 data of bevacizumab activity in combination with chemotherapy in the setting of recurrent platinum-sensitive disease, with evidence of progression-free survival benefit. Overall survival data are not yet mature.
46. NCT00565851. Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer. Available at http://www.clinicaltrials.gov/ct2/show/NCT00565851. Accessed June 2011.
47. NCT00544973. An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-Sensitive Relapsed Ovarian Cancer (ICON6). Available at http://www.clinicaltrials.gov/ct2/show/NCT00544973. Accessed June 2011.
48. Karlan BY, Oza AM, Hansen VL, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma. J Clin Oncol 2010;28(May 20 suppl):Abstract 5000.
49. Ledermann JA, Rustin GJ, Hackshaw A, et al. A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). J Clin Oncol 2009;27(May 20 suppl):Abstract 5501 and in press, Journal of Clinical Oncology.
50. NCT00390611. Paclitaxel and Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients with Ovarian Cancer. Available at http://www.clinicaltrials.gov/ct2/show/NCT00390611. Accessed June 2011.
51. NCT00866697. Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Available at http://www.clinicaltrials.gov/ct2/show/NCT00866697. Accessed June 2011.
52. Han ES, Burger RA, Darcy KM, et al. Relationship between angiogenic markers and clinicopathologic factors/outcome in GOG-170D, a phase II trial of bevacizumab (Bev) in recurrent or persistent epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC). J Clin Oncol 2008;26(May 20 suppl):Abstract 5577.
53. MP Smerdel KD Steffensen M Waldstrom, et al. 2010 The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab Gynecol Oncol 118 2 167 71 20471067 10.1016/j.ygyno.2010.03.018 1:CAS:528:DC%2BC3cXosVGgsr8%3D